Pseudomonas aeruginosa hemolytic phospholipase C suppresses neutrophil respiratory burst activity.
Pseudomonas aeruginosa is a persistent pathogen in the airways of patients with cystic fibrosis or bronchiectasis from other causes and appears to have evolved strategies to survive the inflammatory response of the host. We hypothesized that the secreted hemolytic phospholipase C (PLC) of P. aeruginosa (PlcHR) would decrease neutrophil respiratory burst activity. We found that while intact wild-type P. aeruginosa cells stimulated moderate respiratory burst activity from human neutrophils, an isogenic mutant pseudomonas (DeltaHR strain) containing a targeted deletion of the plcHR operon induced a much more robust oxidative burst from neutrophils. In contrast, a second pseudomonas mutant (DeltaN) containing a disruption in the gene encoding the nonhemolytic PLC (PlcN) was not different from the wild type in stimulating neutrophil O2.- production. Readdition of purified PlcHR to the DeltaHR strain suppressed neutrophil O2.- production to levels stimulated by wild-type bacteria. Interestingly, purified PlcHR decreased phorbol myristate acetate (PMA)- but not formyl methionyl-leucyl-proline (fMLP)-induced respiratory burst activity, suggesting interference by PlcHR with a protein kinase C (PKC)-specific signaling pathway. Accordingly, the PKC inhibitor bisindolylmaleimide inhibited the oxidative burst induced by either PMA or intact pseudomonas, but not by fMLP, whereas the p38 kinase inhibitor SB-203580 fully inhibited the respiratory burst induced by fMLP or the PlcHR-replete wild-type bacteria, but not PMA or the PlcHR-deficient DeltaHR bacterial mutant. We conclude that expression of PlcHR by P. aeruginosa suppresses bacterium-induced neutrophil respiratory burst by interfering with a PKC-dependent, non-p38 kinase-dependent pathway.
Terada
L S
LS
University of Colorado Health Sciences Center, Denver, Colorado 80262, USA. lterada@aol.com
Johansen
K A
KA
Nowbar
S
S
Vasil
A I
AI
Vasil
M L
ML
D001987:Bronchiectasis / Q000150:complications; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000037:antagonists & inhibitors; D003550:Cystic Fibrosis / Q000150:complications; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006461:Hemolysis / Q000502:physiology; D006801:Humans; D066298:In Vitro Techniques; D020928:Mitogen-Activated Protein Kinases; D009154:Mutation; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology / Q000502:physiology*; D009894:Opportunistic Infections / Q000209:etiology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D011552:Pseudomonas Infections / Q000209:etiology; D011550:Pseudomonas aeruginosa / Q000201:enzymology* / Q000235:genetics / Q000472:pathogenicity*; D016897:Respiratory Burst / Q000187:drug effects / Q000502:physiology*; D010738:Type C Phospholipases / Q000502:physiology*; D014774:Virulence / Q000235:genetics / Q000502:physiology; D048051:p38 Mitogen-Activated Protein Kinases
D004791:Enzyme Inhibitors; D011493:Protein Kinase C; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases; D010738:Type C Phospholipases